Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.
IPO Date: April 14, 2004
Sector: Healthcare
Industry: Pharma
Market Cap: $7.55B
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.27 | 2.79%
Avg Daily Range (30 D): $1.16 | 1.57%
Avg Daily Range (90 D): $2.06 | 2.79%
Institutional Daily Volume
Avg Daily Volume: .47M
Avg Daily Volume (30 D): 1.11M
Avg Daily Volume (90 D): 1.28M
Trade Size
Avg Trade Size (Sh.): 104
Avg Trade Size (Sh.) (30 D): 45
Avg Trade Size (Sh.) (90 D): 48
Institutional Trades
Total Inst.Trades: 4,165
Avg Inst. Trade: $2.51M
Avg Inst. Trade (30 D): $5.22M
Avg Inst. Trade (90 D): $4.81M
Avg Inst. Trade Volume: .11M
Avg Inst. Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $3.45M
Avg Closing Trade (30 D): $11.21M
Avg Closing Trade (90 D): $12.85M
Avg Closing Volume: 138.24K
   
News
May 8, 2025 @ 5:00 PM
High- and Low-Grade Serous Ovarian Cancer Market i...
Source: Delveinsight
Dec 11, 2024 @ 6:00 PM
Alcohol Use Disorder Market Set for Remarkable Gro...
Source: Delveinsight
Sep 19, 2024 @ 7:36 PM
Corcept Moves 6.5% Higher: Will This Strength Last...
Source: Zacks
Sep 3, 2024 @ 8:29 PM
Corcept Shares Rise More Than 45% in Six Months: H...
Source: Zacks
Aug 6, 2024 @ 10:20 AM
Should You Invest in the First Trust NYSE Arca Bio...
Source: Zacks Investment Research
Financials
  TTM Q1 2025 Q4 2024
Basic EPS $1.27 $.19 $.29
Diluted EPS $1.15 $.17 $.25
Revenue $ 685.45M $ 157.21M $ 181.89M
Gross Profit $ 674.7M $ 154.81M $ 178.93M
Net Income / Loss $ 133.99M $ 20.55M $ 30.75M
Operating Income / Loss $ 110.87M $ 3.42M $ 25.26M
Cost of Revenue $ 10.75M $ 2.4M $ 2.96M
Net Cash Flow $ -59.93M $ -37.85M $ -9.62M
PE Ratio 0.00